Innovent Biologics

Explore the latest insights on Innovent Biologics and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Innovent Biologics’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Innovent Biologics and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Innovent Biologics's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance
CompanyDeals

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Group and the China Association Against Epilepsy (CAAE) officially signed a strategic collaboration agreement, committing to a five‑year partnership spanning discipline development, talent cultivation and public welfare assistance.…

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Mirxes Partners with Thailand's National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs "Cancer Moonshot 2056"

Mirxes Partners with Thailand’s National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs “Cancer Moonshot 2056”

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting

Company

Innovent Biologics Sees 6.7% Revenue Increase in 2022 Amidst R&D Growth and Product Expansion

CompanyDrug

Innovent Biologics Begins Phase I Trial for IBI333 in Neovascular AMD

CompanyDrug

Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis

CompanyDrug

Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy

Company

Innovent Biologics Posts Strong Q4 Revenues Amid COVID-19 Challenges

CompanyDrug

Innovent Biologics Doses First Patient in Phase III Study for Mazdutide

CompanyDrug

Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications

Show More